In May 2021, the US Food and Drug Administration released a lengthy briefing document on an experimental medication for a rare autoimmune form of vasculitis that often damages the kidneys and lungs. The agency was on the fence about whether to approve the treatment, and it wanted an independent advisory committee to weigh in. Among the questions at hand: Was the drug meaningfully better than existing therapies?
Participants in the study, which had been conducted by the California biotechnology company ChemoCentryx, did appear to have slightly higher rates of symptom remission after one year. But according to the FDA, it was hard to interpret the results because the study’s design had been less than optimal. Some advisory committee members expressed a similar view. The effect of the drug, said one, “is just not well verified by this study.”
At the same time, many patients, and some physicians, saw in the data a potentially helpful medication, one that might lessen patients’ reliance on steroids, which are highly effective but often cause severe side effects.
Get in the spirit with these horrors from YouTube
October 31, 2026
Keyboards of The Verge
October 31, 2026
Binance CEO says 90 percent of stolen assets have been ‘replenished’
October 31, 2026
Happy Pikmin Day Eve
October 31, 2026
I built an AI Tamagotchi before Meta could
October 31, 2026
Windows 11 tries new shortcuts for Xbox gaming mode and search
October 31, 2026
Petrol and diesel prices today, November 1: Check fuel rates in different cities across India
November 1, 2026
Rahul Gandhi rally protest today, Nov 1: Check full traffic advisory, road diversions, railway, bus, metro routes here
November 1, 2026
India readies a new soft power playbook
November 1, 2026
How the downfall of Serbia's Vučiċ mirrored that of Hungary's Orbán
November 1, 2026
India's opposition set to hold mega rally seeking election chief's resignation
November 1, 2026
Daniel Wilkerson's Funny Car explodes in massive fireball during NHRA qualifying; video emerges
October 31, 2026